<DOC>
	<DOCNO>NCT00945282</DOCNO>
	<brief_summary>GSK in-licensed novel NNRTI-class candidate ( GSK2248761 , IDX12899 ) treatment subject HIV-1 infection Idenix Pharmaceuticals . Idenix Pharmaceuticals complete proof-of-concept study evaluate GSK2248761 monotherapy seven day forty treatment-naïve subject infect HIV-1 . GSK2248761 dose sequentially evaluate 800 mg QD , 400 mg QD , 200 mg QD 100mg QD . This study evaluate low dose , dos , GSK2248761 good characterize dose-response concentration-response curve . The result study used select dose future clinical study HIV-1 infected subject .</brief_summary>
	<brief_title>Safety Tolerability Study Evaluate Lower Dose GSK2248761 Antiretroviral Treatment-Naive HIV-1 Infected Adults .</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Male Female , 21 65 year age . Female nonchildbearing potential define : postmenopausal , define 12 month spontaneous amenorrhea serum FSH level &gt; 40 MIU/ml Screening OR document bilateral tubal ligation hysterectomy least 6 month prior study initiation , bilateral oophorectomy bilateral tubal ligation . Plasma HIV1 RNA value &gt; = 5000 copies/mL . CD4+ count &gt; = 200 cells/mm3 . Is antiretroviral treatmentnaïve agree start antiretroviral therapy prior clinic checkin ( Day1 ) . Subject agree start standard HAART regimen Day 8 study Kaletra monotherapy 28 day within 24 hour last dose study medication . Capable give write informed consent , include willing able comply requirement restriction list consent form . Subject pregnant determine positive urine/serum pregnancy test Screening Day 1 . Lactating female . Male subject reproductive potential unwilling use double barrier method contraception ( e.g. , condom plus spermicide ) continue use adequate method birth control least 30 day last dose study drug . Has positive screening Hepatitis B surface antigen , positive screening Hepatitis C virus ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) subsequent test . If Hepatitis C antibody positive HCV RNA undetectable , subject may include study . History regular alcohol consumption within 6 month Screening define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit Has positive prestudy drug screen . Drugs screen include amphetamine , barbiturate , cocaine PCP . History sensitivity study medication , component thereof , history drug allergy , opinion Principal Investigator , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Note : Study drug include GSK2248761 placebo followup HAART Kaletra therapy . Received immunomodulating agent ( e.g. , interleukin2 ) immunotherapeutic vaccine within 30 day Day 1 . Requires medication know substrate , inhibitor and/or inducer CYP3A4 . Has receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose day . Has ever AIDSdefining illness . Has history currently active clinically important disease HIV1 infection , opinion Investigator , may put subject risk participation study ( include renal hepatic impairment , active infection include tuberculosis opportunistic infection , malignancy cardiac dysfunction ) . Has intestinal malabsorption ( e.g. , structural defect , digestive failure , enzyme deficiency , etc ) . Has preexist NNRTI drug resistance base genotyping Screening . Where participation study would result donation blood blood product excess 500mL within 56 day period . Subject follow laboratory parameter Screening ( single repeat allow eligibility determination ) : Hemoglobin &lt; 8.5 g/dL , Neutrophil count &lt; 1000 cells/mm3 , Platelet count &lt; 100,000 cells/mm3 , Serum creatinine &gt; upper limit normal ( ULN ) , AST ALT &lt; = 2.5 x ULN . Exclusion Criteria Screening ECG ( A single repeat allow eligibility determination ) : Exclusion Criteria Screening ECG : Heart rate : ( male ) &lt; 45 &gt; 100 bpm ( female ) &lt; 50 &gt; 100 bpm , QRS duration : &gt; 120 msec , QTc interval ( Bazett ) : &gt; 450 msec . Nonsustained ( &gt; = 3 consecutive beat ) sustain ventricular tachycardia . Sinus Pauses &gt; 2.5 second . 2nd degree ( Type II ) high AV block . Evidence previous myocardial infarction ( pathologic Q wave , ST segment change ( except early repolarization ) ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>IDX12899</keyword>
	<keyword>adaptive</keyword>
	<keyword>monotherapy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Treatment-naive</keyword>
	<keyword>HIV-1</keyword>
	<keyword>GSK2248761</keyword>
	<keyword>NNRTI</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>treatment naive</keyword>
</DOC>